Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0648

+8.0%

Nov 11 3:24 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Littlebits

From: Howard Williams	10/4/2013 11:34:53 AM
	1 Recommendation of 13111

Two more articles about PV-10 arising from the poster session at ECCO last Monday. ECC 2013: PV-10 in Metastatic Melanoma: blistering predicts good outcomes 04 Oct 2013 by ecancer reporter Janet Fricker [author of an earlier article] ............... http://ecancer.org/news/4542-ecc-2013-- … tcomes.php Intralesional PV-10 Shows High Response Rate in Advanced Melanoma, Evidence of Systemic Effects:: Presented at ECCO-ESMO-ESTRO Congress October 3rd, 2013 ........... http://www.firstwordpharma.com/node/114 … z2glSP7UWc ************************ The 2013 European Cancer Congress is the 17th congress of the European CanCer Organisation (ECCO), the 38th congress of the European Society for Medical Oncology (ESMO), and the 32nd congress of European Society for Therapeutic Radiology and Oncology (ESTRO).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next